Combination therapy for belly fluid from digestive cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs and focused radiation to treat belly fluid caused by digestive system cancers. It aims to shrink tumors and reduce fluid buildup, potentially improving symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have fluid in the belly (ascites) that is known to be caused by cancer from the digestive system.
- You must have a tumor or mass in the belly that is at least 2 inches (5 cm) across, or one that is pressing on your belly wall and causing pain.
- You must have a moderate or large amount of belly fluid, either for the first time or after not responding to other treatments.
- You must be able to take care of yourself and be out of bed more than half the day (a score of 0, 1, or 2 on a standard activity scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This study tests a combination of two treatments for stomach cancer that has spread to the lining of the belly. It uses an immunotherapy drug (tislelizumab) plus standard chemotherapy (SOX) and a heated chemotherapy treatment directly into the belly (HIPEC) to see if this approach is safe and effective.
This trial tests a drug called rmhTNF that is put directly into the abdomen (the belly area) to help prevent or treat cancer that has spread there (called peritoneal metastasis) and to reduce fluid buildup (called malignant ascites). The goal is to see if this treatment can help control the cancer and improve symptoms in people with advanced stomach or colorectal cancer.
Hear when a new Digestive System Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.